Skip to main content
Ahmad Awada, MD, Obstetrics & Gynecology, Detroit, MI

Ahmad Awada MD

Gynecologic Oncology


Gynecology Oncology

Join to View Full Profile
  • 3031 W Grand BlvdDetroit, MI 48202

  • Phone+1 313-916-2464

Dr. Awada is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • George Washington University
    George Washington UniversityResidency, Obstetrics and Gynecology, 2010 - 2014
  • American University of Beirut Faculty of Medicine
    American University of Beirut Faculty of MedicineClass of 2009

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 2024 - 2027
  • FL State Medical License
    FL State Medical License 2021 - 2025
  • NY State Medical License
    NY State Medical License 2018 - 2021
  • PA State Medical License
    PA State Medical License 2014 - 2021
  • VA State Medical License
    VA State Medical License 2010 - 2014
  • DC State Medical License
    DC State Medical License 2010 - 2012
  • Obstetrics & Gynecology
    American Board of Obstetrics and Gynecology Obstetrics & Gynecology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Anti-tumor activity of PM1183 (lurbinectedin) in combination with capecitabine in metastatic breast cancer patients: Results from a phase I trial. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • PharmaMar Announces Data Presentations for Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018
    PharmaMar Announces Data Presentations for Both Its Molecules Yondelis® and Lurbinectedin at ASCO 2018August 3rd, 2018
  • ‘Fighting My Cancer as Much as Possible’: Why Many Patients Join Phase 1 Clinical Trials
    ‘Fighting My Cancer as Much as Possible’: Why Many Patients Join Phase 1 Clinical TrialsMarch 8th, 2018
  • Neratinib plus Paclitaxel vs. Trastuzumab plus Paclitaxel in Breast Cancer
    Neratinib plus Paclitaxel vs. Trastuzumab plus Paclitaxel in Breast CancerApril 14th, 2016

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: